Payment overview · 2025
General Payments
$624.82
34 reported records · 16 companies
Healthcare provider profile · identity verified
Ellis L Malone, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AUSTELL, GA · NPI 1326037821
Verified facts
What the public records show
CMS Open Payments records show Ellis L Malone, MD received $624.82 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.66 | 25.2% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.17 | 10.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.65 | 10.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $35.94 | 5.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.86 | 5.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.55 | 5.7% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $28.99 | 4.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.60 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.31 | 4.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.42 | 4.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.74 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.20 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.08 | 3.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.95 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.07 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.63 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $624.82 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.95 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.47 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.17 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.65 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.15 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.60 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 416 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 160 |
| Gabapentin | Gabapentin | 289 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 115 |
| Alprazolam | Alprazolam | 261 | 70 |
| Metformin Hcl | Metformin Hcl | 246 | 102 |
| Lisinopril | Lisinopril | 243 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 231 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 96 |
| Losartan Potassium | Losartan Potassium | 156 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 135 | 30 |
| Tramadol Hcl | Tramadol Hcl | 130 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 37 |
| Furosemide | Furosemide | 118 | 44 |
| Clonazepam | Clonazepam | 110 | 27 |
| Carvedilol | Carvedilol | 109 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 37 |
| Sertraline Hcl | Sertraline Hcl | 90 | 39 |
| Omeprazole | Omeprazole | 86 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 26 |
| Simvastatin | Simvastatin | 83 | 39 |
| Trazodone Hcl | Trazodone Hcl | 82 | 29 |
| Mirtazapine | Mirtazapine | 81 | 22 |
| Meloxicam | Meloxicam | 80 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 35 |
| Ezetimibe | Ezetimibe | 75 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 24 |
| Methylprednisolone | Methylprednisolone | 73 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 29 |
| Jardiance | Empagliflozin | 71 | 25 |
| Lorazepam | Lorazepam | 71 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 35 |
| Sulindac | Sulindac | 71 | 32 |
| Metformin Hcl Er | Metformin Hcl | 70 | 31 |
| Indapamide | Indapamide | 69 | 30 |
| Spironolactone | Spironolactone | 69 | 23 |
| Donepezil Hcl | Donepezil Hcl | 68 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 19 |
| Eliquis | Apixaban | 63 | 23 |
| Ozempic | Semaglutide | 62 | 19 |
| Glipizide | Glipizide | 57 | 21 |
| Alendronate Sodium | Alendronate Sodium | 56 | 24 |
| Allopurinol | Allopurinol | 55 | 22 |
| Famotidine | Famotidine | 53 | 15 |
| Promethazine Hcl | Promethazine Hcl | 53 | 19 |
| Torsemide | Torsemide | 53 | 22 |
| Farxiga | Dapagliflozin Propanediol | 52 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 27 |
| Lovastatin | Lovastatin | 50 | 19 |
| Ondansetron Odt | Ondansetron | 50 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 32 |
| Topiramate | Topiramate | 49 | 18 |
| Ibuprofen | Ibuprofen | 48 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 15 |
| Prednisone | Prednisone | 45 | 23 |
| Potassium Chloride | Potassium Chloride | 44 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 19 |
| Bupropion Xl | Bupropion Hcl | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 26 |
| Glipizide Er | Glipizide | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 16 |
| Pregabalin | Pregabalin | 39 | 14 |
| Diazepam | Diazepam | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 19 |
| Baclofen | Baclofen | 37 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 21 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | 12 |
| Linzess | Linaclotide | 34 | 11 |
| Glimepiride | Glimepiride | 33 | 14 |
| Colchicine | Colchicine | 32 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 13 |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 12 |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Cephalexin | Cephalexin | 24 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | 11 |
| Estradiol | Estradiol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $624.82 · 34 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, INSPIRE, Kerendia, LEQEMBI, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TZIELD, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error